Fibrocell Science Inc (FCSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Fibrocell Science Inc (FCSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH214199D
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company's product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic epidermolysis bullosa; FCX-013 for linear scleroderma; and a research program for the treatment of arthritis and related conditions. Fibrocell Science utilizes its proprietary autologous fibroblast technology to develop personalized biologics for skin diseases. It has a manufacturing facility in Exton, Pennsylvania; and operates along with its subsidiaries in the US and Switzerland. Fibrocell Science is headquartered in Exton, Pennsylvania, the US.

Fibrocell Science Inc (FCSC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Fibrocell Science Enters into Agreement with Intrexon 12

Fibrocell Science Enters Into Co-Development Agreement With Intrexon 13

Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14

Fibrocell Science Amends Co-Development Agreement with Intrexon 15

Licensing Agreements 16

Fibrocell Science Enters into Licensing Agreement with Intrexon 16

Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18

Fibrocell Science Enters Into Licensing Agreement With University of California 19

Equity Offering 20

Fibrocell Science Raises USD4 Million in Direct Offering of Shares 20

Fibrocell Science Raises USD6 Million in Private Placement of Shares 22

Fibrocell Science Raises Public Offering of Shares and Warrants for USD10.5 Million 23

Fibrocell Science Raises USD8 Million in Private Placement of Series A Preferred Stock and Warrants 25

Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 26

Fibrocell Raises USD17.3 Million in Public Offering of Shares 27

Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 50.5 Million 29

Fibrocell Science Completes Private Placement Of Shares For USD 45 Million 31

Fibrocell Science Completes Second Tranche Of Private Placement For USD 5.8 Million 33

Debt Offering 34

Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 34

Acquisition 35

Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 35

Fibrocell Science Inc-Key Competitors 36

Fibrocell Science Inc-Key Employees 37

Fibrocell Science Inc-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Joint Venture 38

Recent Developments 39

Financial Announcements 39

Aug 09, 2018: Fibrocell Reports second quarter 2018 financial results and recent highlights 39

May 10, 2018: Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights 41

Mar 19, 2018: Fibrocell Announces 2017 Financial Results 43

Nov 13, 2017: Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights 45

Aug 09, 2017: Fibrocell Reports Second Quarter 2017 Financial Results and Recent Highlights 47

May 10, 2017: Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights 48

Mar 09, 2017: Fibrocell Reports 2016 Financial Results and Recent Operational Highlights 49

Product Approvals 51

Feb 05, 2018: Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma 51

Jun 12, 2017: Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma 52

Clinical Trials 53

May 09, 2017: Fibrocell and Intrexon Announces Data on FCX-013 at the 20th Annual Meeting of the American Society of Gene & Cell Therapy 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Fibrocell Science Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Fibrocell Science Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Fibrocell Science Inc, Medical Devices Deals, 2012 to YTD 2018 10

Fibrocell Science Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Fibrocell Science Enters into Agreement with Intrexon 12

Fibrocell Science Enters Into Co-Development Agreement With Intrexon 13

Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 14

Fibrocell Science Amends Co-Development Agreement with Intrexon 15

Fibrocell Science Enters into Licensing Agreement with Intrexon 16

Fibrocell Science Enters into Licensing Agreement with University of California to Advance the Development of Personalized Cell Therapies 18

Fibrocell Science Enters Into Licensing Agreement With University of California 19

Fibrocell Science Raises USD4 Million in Direct Offering of Shares 20

Fibrocell Science Raises USD6 Million in Private Placement of Shares 22

Fibrocell Science Raises Public Offering of Shares and Warrants for USD10.5 Million 23

Fibrocell Science Raises USD8 Million in Private Placement of Series A Preferred Stock and Warrants 25

Fibrocell Science to Raise up to USD50 Million in Public Offeirng of Shares 26

Fibrocell Raises USD17.3 Million in Public Offering of Shares 27

Fibrocell Science Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For USD 50.5 Million 29

Fibrocell Science Completes Private Placement Of Shares For USD 45 Million 31

Fibrocell Science Completes Second Tranche Of Private Placement For USD 5.8 Million 33

Fibrocell Science Raises USD18.1 Million in Private Placement of Notes and Warrants 34

Rohto Pharma Completes Acquisition Of 57% Stake In Agera Labs, Skincare Company 35

Fibrocell Science Inc, Key Competitors 36

Fibrocell Science Inc, Key Employees 37

Fibrocell Science Inc, Subsidiaries 38

Fibrocell Science Inc, Joint Venture 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Fibrocell Science Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17825
Site License
USD 500 INR 35650
Corporate User License
USD 750 INR 53475

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com